See more : Envoy Medical, Inc. (COCHW) Income Statement Analysis – Financial Results
Complete financial analysis of SOHM, Inc. (SHMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SOHM, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Singapore Land Group Limited (UILCF) Income Statement Analysis – Financial Results
- Enersize Oyj (ENERS.ST) Income Statement Analysis – Financial Results
- Waseco Resources Inc. (WSRUF) Income Statement Analysis – Financial Results
- FirstGroup plc (FGROY) Income Statement Analysis – Financial Results
- Mediobanca Banca di Credito Finanziario S.p.A. (MDIBF) Income Statement Analysis – Financial Results
SOHM, Inc. (SHMN)
About SOHM, Inc.
SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States. It offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products. The company also exports its products. SOHM, Inc. was founded in 2005 and is based in Corona, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 402.65K | 347.09K | 324.91K | 235.08K | 162.90K | 422.99K | 173.96K | 124.26K | 278.14K |
| Cost of Revenue | 145.48K | 161.71K | 151.29K | 144.68K | 38.49K | 218.95K | 70.59K | 30.26K | 450.19K |
| Gross Profit | 257.16K | 185.37K | 173.61K | 90.40K | 124.41K | 204.04K | 103.37K | 94.01K | -172.05K |
| Gross Profit Ratio | 63.87% | 53.41% | 53.43% | 38.45% | 76.37% | 48.24% | 59.42% | 75.65% | -61.86% |
| Research & Development | 22.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 530.11K | 91.34K | 84.29K | 56.55K | 80.10K | 151.62K | 167.24K | 114.16K | 230.29K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 552.16K | 91.34K | 84.29K | 56.55K | 80.10K | 151.62K | 167.24K | 114.16K | 230.29K |
| Cost & Expenses | 697.65K | 253.05K | 235.59K | 201.23K | 118.58K | 370.57K | 237.83K | 144.42K | 680.48K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.90K | 1.46K | 1.04K | 755.00 | 1.18K | 273.00 | 270.00 | 1.66K | 234.81K |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 4.40K | 52.52K | 22.82K | 141.86K |
| EBITDA | -295.00K | 94.04K | 89.32K | 33.85K | 44.31K | 56.82K | -63.87K | -20.16K | -260.48K |
| EBITDA Ratio | -73.27% | 27.09% | 27.49% | 14.40% | 27.20% | 13.43% | -36.72% | -16.22% | -93.65% |
| Operating Income | -295.00K | 94.04K | 89.32K | 33.85K | 44.31K | 52.42K | -63.87K | -20.16K | -402.34K |
| Operating Income Ratio | -73.27% | 27.09% | 27.49% | 14.40% | 27.20% | 12.39% | -36.72% | -16.22% | -144.65% |
| Total Other Income/Expenses | -1.90K | -1.46K | -1.04K | -756.00 | -1.18K | -273.00 | -270.00 | -1.66K | -234.81K |
| Income Before Tax | -296.90K | 92.58K | 88.28K | 33.09K | 43.13K | 52.15K | -64.14K | -21.82K | -637.15K |
| Income Before Tax Ratio | -73.74% | 26.67% | 27.17% | 14.08% | 26.48% | 12.33% | -36.87% | -17.56% | -229.07% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | -171.86K | -156.74K | -52.52K | -22.82K | -5.00 |
| Net Income | -296.90K | 92.58K | 88.28K | 33.09K | 43.13K | 52.15K | -64.14K | -21.82K | -637.15K |
| Net Income Ratio | -73.74% | 26.67% | 27.17% | 14.08% | 26.48% | 12.33% | -36.87% | -17.56% | -229.07% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.60B | 1.58B | 1.58B | 1.58B | 1.56B | 1.55B | 1.44B | 1.44B | 1.55B |
| Weighted Avg Shares Out (Dil) | 1.60B | 1.58B | 1.58B | 1.58B | 1.56B | 1.55B | 1.44B | 1.44B | 1.55B |
SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
CHINO HILLS, CA / ACCESSWIRE / November 20, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has appointed Dr. Wei Zhu as its Senior Marketing and Sales...
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
For Pharmaceutical, Nutraceutical, Cosmeceutical & Strategic Partnered Products CHINO HILLS, CA / ACCESSWIRE / November 14, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today receipt of the Official Notice Of...
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
CHINO HILLS, CA / ACCESSWIRE / October 2, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has filed new provisional patent application with USPTO. Dr. David Aguilar,...
SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders
CHINO HILLS, CA / ACCESSWIRE / September 25, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has received ABBIE Technology kits pre-launch orders. Dr. David Aguilar, COO,...
SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
CHINO HILLS, CA / ACCESSWIRE / August 2, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced today the appointment of Dr. Tetsuya Kawamura,...
SOHM, Inc. has signed the Manufacturing and Supply of Skincare Topical Products with New Export Customers
CHINO HILLS, CA / ACCESSWIRE / July 30, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today the dispatch of its first initial purchase order for manufacturing and supplying skincare products...
SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
CHINO HILLS, CA / ACCESSWIRE / July 25, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnologycompany that manufactures and markets generic drugs covering numerous treatment categories, announced that it has signed a new agreement with...
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor
CHINO HILLS, CA / ACCESSWIRE / June 10, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced that preliminary data from a 3rd party...
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
SOHM, Inc. Further Advances its Work in the Field of Genome Editing and ABBIE, a Retroviral Integrase with Linked Guided DNA Binding Domain SOHM, Inc. Further Advances its Work in the Field of Genome Editing and ABBIE, a Retroviral Integrase...
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
CHINO HILLS, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today the collaboration with Coastar Therapeutics, San Diego, California, a...
Source: https://incomestatements.info
Category: Stock Reports